- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial | 4 | Benzinga.com | ||
| 27.08. | Wechsel im Verwaltungsrat von Vor Biopharma: Drei Rücktritte und eine Neubesetzung | 4 | Investing.com Deutsch | ||
| 27.08. | Vor Bio, RemeGen late-stage trial of telitacicept in IgA nephropathy meets primary goal | 2 | Seeking Alpha | ||
| 27.08. | Vor Biopharma stock rises after collaborator's IgAN drug hits endpoint | 2 | Investing.com | ||
| 27.08. | Vor Biopharma: Aktionäre genehmigen Änderungen am Aktienplan und Aktienzusammenlegung | 3 | Investing.com Deutsch | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.08. | Telitacicept von Vor Bio erreicht primären Endpunkt in Studie zu IgA-Nephropathie | 2 | Investing.com Deutsch | ||
| 27.08. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Vor Bio's telitacicept meets primary endpoint in IgA nephropathy trial | 2 | Investing.com | ||
| 18.08. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 168 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August... ► Artikel lesen | |
| 13.08. | Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate | 2 | Benzinga.com | ||
| 13.08. | Vor Bio: RemeGen Achieves Primary Endpoint In Phase 3 Study In China Evaluating Telitacicept | 3 | RTTNews | ||
| 13.08. | Vor Biopharma: Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor | 222 | GlobeNewswire (Europe) | Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3... ► Artikel lesen | |
| 12.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 10 | SEC Filings | ||
| 07.08. | Vor Bio hires commercial chief, reuniting ex-Sarepta colleagues in freshly rebuilt C-suite | 2 | FiercePharma | ||
| 04.08. | Vor Biopharma: Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer | 190 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment... ► Artikel lesen | |
| 22.07. | Vor Biopharma Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 21.07. | Vor Bio appoints two industry veterans to its board of directors | 1 | Investing.com | ||
| 21.07. | Vor Biopharma: Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 18.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 211 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
| 17.07. | Vor Biopharma: Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer | 173 | GlobeNewswire (Europe) | Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience... ► Artikel lesen |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,365 | -0,13 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,031 | -5,45 % | SOL Global Investments Corp.: SOL Global Appoints Hex Trust as Strategic Web3 Partner to Execute Institutional Digital Asset Strategy | Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") on 23 July, 2025, appointed Hex Trust, a leading... ► Artikel lesen | |
| TRINITY BIOTECH | 1,095 | 0,00 % | Trinity Biotech plc: Trinity Biotech Regains Compliance with Nasdaq Listing Requirements | DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,839 | +2,02 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 17,845 | +0,08 % | Forecasting The Future: 5 Analyst Projections For Arcturus Therapeutics | ||
| OVID THERAPEUTICS | 1,000 | -5,66 % | Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions... ► Artikel lesen | |
| EQUILLIUM | 1,740 | +8,48 % | Equillium, Inc. - 8-K, Current Report | ||
| 4D MOLECULAR THERAPEUTICS | 6,960 | -4,26 % | Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec" | ||
| REGENCELL BIOSCIENCE | 13,500 | +1,89 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| GENERATION BIO | 5,830 | -3,48 % | Generation Bio Co.: Generation Bio Announces 1-for-10 Reverse Stock Split | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases... ► Artikel lesen | |
| CABALETTA BIO | 1,685 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| LONGEVERON | 0,840 | 0,00 % | Longeveron Announces Key Leadership Updates | Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el... ► Artikel lesen | |
| PROKIDNEY | 2,170 | 0,00 % | ProKidney auf Morgan-Stanley-Konferenz: Strategische Einblicke in die Therapie chronischer Nierenerkrankungen | ||
| BOLT PROJECTS | 3,730 | 0,00 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| ATHIRA PHARMA | 0,385 | -1,36 % | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,960 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.